ALN-AAT02 is Alnylam’s first investigational RNAi therapeutic utilizing the Company’s enhanced stabilization chemistry plus (ESC+) GalNAc-conjugate technology. Alnylam ALN-AAT02 program lead vice president Thomas Hoock said: “We are
The post Alnylam seeks MHRA approval to start ALN-AAT02 phase 1/2 trial appeared first on Pharma Business review.
Original Article: Alnylam seeks MHRA approval to start ALN-AAT02 phase 1/2 trial